Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

Autor: Jennifer De Cremer, Julia Katharina Schwarze, Christophe Leys, Jan L. Bernheim, Anne Rogiers, Adrian Schembri, Gil Awada, Justine Lauwyck, Bart Neyns, Mark De Ridder, Peter Theuns, Paul Maruff
Přispěvatelé: Faculty of Medicine and Pharmacy, Radiation Therapy, Physics, Medical Oncology, Clinical sciences, Internal Medicine, Psychology, Faculty of Psychology and Educational Sciences, Brain, Body and Cognition, End-of-life Care Research Group, Translational Radiation Oncology and Physics, Vriendenkring VUB, Laboratory for Medical and Molecular Oncology, Laboratory of Molecullar and Cellular Therapy
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Pediatrics
STRESS
SYMPTOMS
EUROPEAN-ORGANIZATION
Anxiety
FATIGUE
0302 clinical medicine
Cognition
Quality of life
Surveys and Questionnaires
Medicine and Health Sciences
Immunology and Allergy
030212 general & internal medicine
Survivors
Melanoma
Depression (differential diagnoses)
Fatigue
SCALE
Aged
80 and over
Depression
General Medicine
MULTIPLE-SCLEROSIS
Middle Aged
Mental Status and Dementia Tests
DEPRESSION
humanities
030220 oncology & carcinogenesis
Female
medicine.symptom
Psychosocial
medicine.drug
Adult
medicine.medical_specialty
Article Subject
Immunology
Ipilimumab
HOSPITAL ANXIETY
CANCER-PATIENTS
VALIDATION
03 medical and health sciences
medicine
Humans
Adverse effect
Aged
Hepatitis
business.industry
Généralités
social sciences
RC581-607
medicine.disease
Clinical Study
Quality of Life
Immunologic diseases. Allergy
Neoplasm Recurrence
Local
business
Neurocognitive
Stress
Psychological
Zdroj: JOURNAL OF IMMUNOLOGY RESEARCH
Journal of Immunology Research, 2020
Journal of Immunology Research
Journal of Immunology Research, Vol 2020 (2020)
ISSN: 1432-0142
2314-8861
2314-7156
Popis: Purpose. To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods. Melanoma survivors were identified within two study populations (N=104), at a single-center university hospital, and defined as patients who were disease-free for at least 2 years after initiating IPI. Data were collected using 4 patient-reported outcome measures, computerized NCF testing, and a semistructured interview at the start and 1-year follow-up. Results. Out of 18 eligible survivors, 17 were recruited (5F/12M); median age is 57 years (range 33-86); and median time since initiating IPI was 5.6 years (range 2.1-9.3). The clinical interview revealed that survivors suffered from cancer-related emotional distress such as fear of recurrence (N=8), existential problems (N=2), survivor guilt (N=2), and posttraumatic stress disorder (N=6). The mean EORTC QLQ-C30 Global Score was not significantly different from the European mean of the healthy population. Nine survivors reported anxiety and/or depression (Hospitalization Depression Scale) during the survey. Seven survivors (41%) reported fatigue (Fatigue Severity Scale). Seven patients (41%) had impairment in NCF; only three out of seven survivors had impairment in subjective cognition (Cognitive Failure Questionnaire). Anxiety, depression, fatigue, and neurocognitive symptoms remained stable at the 1-year follow-up. All cases of skin toxicity (N=8), hepatitis (N=1), colitis (N=3), and sarcoidosis (N=1) resolved without impact on HRQoL. Three survivors experienced hypophysitis; all suffered from persistent fatigue and cognitive complaints 5 years after onset. One survivor who experienced a Guillain-Barré-like syndrome suffered from persisting depression, fatigue, and impairment in NCF. Conclusion. A majority of melanoma survivors treated with IPI continue to suffer from emotional distress and impairment in NCF. Timely detection in order to offer tailored care is imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE. The trial is registered with B.U.N. 143201421920.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: